why choose us

First received: December 16, 2022

Clinical Trial: Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Study Status: Completed

Recruit Status: RECRUITING

Condition: Carcinoma, Non-Small-Cell Lung

Study Type: INTERVENTIONAL


Official Title: Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib T

Brief Summary: The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.

Read more